Drugs.com - New Drug Approvals

FDA Approves Gomekli (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

STAMFORD, Conn., Feb. 11, 2025 -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has approved...

Feb 12, 2025 - 00:36
 0
FDA Approves Gomekli (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
STAMFORD, Conn., Feb. 11, 2025 -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has approved...
Read More

Tags:

Previous Article

Solutions for Every Hold

Next Article

Simple Congenital Heart Diseases Tied to Higher Epilepsy Risk

Related Posts

FDA Approves Tremfya (guselkumab) for Adult Patients with Moderately to Severely Active Crohn’s Disease

FDA Approves Tremfya (guselkumab) for Adult Patients wi...

Mar 24, 2025  0

Enhertu Approved as First HER2-Directed Therapy for Patients with HER2-Low or HER2-Ultralow Metastatic Breast Cancer

Enhertu Approved as First HER2-Directed Therapy for Pat...

Feb 9, 2025  0

FDA Approves Novartis Radioligand Therapy Pluvicto for Earlier Use Before Chemotherapy in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

FDA Approves Novartis Radioligand Therapy Pluvicto for ...

Mar 29, 2025  0